Fezakinumab
Fezakinumab is an experimental drug that is being studied for the treatment of various autoimmune diseases. It is a human monoclonal antibody that targets the interleukin-22 (IL-22) protein, a cytokine involved in inflammatory responses.
Mechanism of Action[edit | edit source]
Fezakinumab works by binding to the IL-22 protein and preventing it from interacting with its receptor on the surface of cells. This blocks the signal that triggers inflammation, thereby reducing the symptoms of autoimmune diseases.
Clinical Trials[edit | edit source]
Fezakinumab has been tested in several clinical trials for conditions such as psoriasis, rheumatoid arthritis, and Crohn's disease. While results have been promising, further research is needed to determine the drug's long-term safety and efficacy.
Side Effects[edit | edit source]
As with any drug, fezakinumab may cause side effects. These can include nausea, headache, and injection site reactions. Patients should discuss potential side effects with their healthcare provider before starting treatment.
Future Research[edit | edit source]
Future research on fezakinumab will focus on determining the optimal dosing regimen, understanding how the drug works in different patient populations, and exploring its potential use in other autoimmune diseases.
See Also[edit | edit source]
Fezakinumab Resources | ||
---|---|---|
|
|
Translate to: East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD